---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-24-000033"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2024-10-03T23:59:59+00:00"
generated_at: "2026-05-30T21:29:43.715363+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# AbbVie cuts 2024 adjusted EPS guidance by $0.04 on $82M Q3 IPR&D charge

## Summary
- Q3 2024 acquired IPR&D & milestones expense of $82M pre-tax, reducing GAAP and adjusted EPS by $0.04.
- Q3 2024 adjusted diluted EPS guidance range now $2.88–$2.92, including the charge.
- Full-year 2024 adjusted diluted EPS guidance revised to $10.67–$10.87 from $10.71–$10.91.
- Guidance excludes any IPR&D expense beyond Q3 2024 due to forecasting uncertainty.
- Q3 2024 results are preliminary and subject to final closing procedures.

## SEC filing metadata
- accession: 0001551152-24-000033
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2024-10-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000033/0001551152-24-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000033/abbv-20241003.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-24-000033
- JSON: https://secwatch.observer/filing/0001551152-24-000033.json
- Plain text: https://secwatch.observer/filing/0001551152-24-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.